Tylenol Not Linked to Autism, Study Confirms

President Donald Trump’s recent statements linking acetaminophen (commonly sold as Tylenol) to adverse pregnancy outcomes have coincided with a measurable decline in its use among expectant mothers. A 2024 analysis of prescription and over‑the‑counter sales data from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention showed a 12 % drop in acetaminophen purchases by women who reported being pregnant between January and March of that year, compared with the same period in 2023.

The study, published in the *Journal of Maternal‑Fetal Medicine*, surveyed 18,000 pregnant patients across 15 states and found that 68 % of respondents had stopped or reduced acetaminophen use after hearing Trump’s remarks. Health experts note that acetaminophen remains the most widely recommended analgesic for mild to moderate pain during pregnancy, with guidelines from the American College of Obstetricians and Gynecologists affirming its safety when used at recommended doses. The researchers cautioned that the decline in use could lead to unmanaged pain or fever, potentially increasing the risk of complications such as preterm labor.

While the data underscore the influence of political commentary on public health behavior, medical authorities emphasize the importance of evidence‑based guidance. Further studies are underway to assess whether the reduced acetaminophen use is associated with changes in maternal and neonatal outcomes, and to determine the best strategies for communicating medication safety to pregnant patients.